Objective: Previous studies and case observations have suggested that dopamine agonists (DAAs) such as pramipexole (PPX) and ropinirole (RPN) might be effective for major depression, but their adjunctive use in treatment-resistant bipolar II depression has not yet been specifically addressed. Method: A chart review was conducted on 18 patients with a DSM-III-R bipolar NOS (Bipolar II) major depressive episode who were admitted to the day-hospital of the Department of Psychiatry at the University of Pisa. DAAs were added to ongoing treatments with conventional antidepressants and mood stabilizers to which patients had no responded after a period of at least 8 weeks. Clinical state and adverse effects were assessed at each visit. Final improvement in CGI scores of 1 or 2 were considered as responders. Results: Mean DAA trial duration was 17.6 (sd = 7.8, range 4 - 34) weeks, with a mean final dose of 1.23 ± 0.32 mg/day (range, 0.75 - 1.50 mg/day) for PPX, and 2.97 ± 0.99 mg/day (range, 1.50 - 5.00 mg/day) for RPN. DAAs were well tolerated and did not show any negative interaction with concomitant psychotropic medications. Only one patient became worse (final CGI = 5), and had to interrupt PPX due to nausea, increased agitation and irritability. Eight patients (44.4 %) were considered responders (4 with PPX and 4 with RPN): 5 showed marked improvement (CGI = 1), and 3 showed moderate improvement (CGI = 2); another 5 (27.8 %) manifested a transient response not sustained up to the end. The initial and final scores of CGI severity scale for all patients (responders and non-responders combined) were, respectively, 5.33 ± 0.7 and 3.94 ± 1.3 (mean ± S.D). The mean change according to the CGI severity scale was statistically significant (t = 4.74. p < 0.0002). Conclusion: From the results, PPX and RPN appear to be well tolerated and potentially useful in the adjunctive treatment of drug-resistant bipolar II depression.
Literatur
-
1
Agnoli A, Ruggieri S, Casacchia M.
Restatement and perspectives of ergot alkaloids in clinical neurology and psychiatry.
Pharmacol.
1978;
16
(1)
174-188
-
2
Bode L, Dietrich E, Stoyloff R, Emrich H M, Ludwig H.
Amantadine and human Borna disease virus in an infected patient with bipolar depression.
Lancet.
1997;
349
178-179
-
3
Bouckoms A, Mangini L.
Pergolide. An antidepressant Adjuvant for Mood Disorders.
Psychopharmacol Bull.
1993;
29
207-211
-
4
Bouras N, Bridges P K.
Bromocriptine and depression.
Curr Med Res Opin.
1982;
8
150-153
-
5
Cassano G B, Akiskal H S, Musetti L, Perugi G, Soriani A, Mignani V.
Psychopathology, Temperament and Past Course in Primary Major Depressions. 2. Toward a redefinition of bipolarity with a New Semi structured Interview for Depression.
Psychopat.
1989;
22
278-288
-
6 Cassano G B, Musetti L, Perugi G, Mignani V, Soriani A, McNair D M, Akiskal H S. Major depression subcategories: their potentiality for clinical research. In: Sanofi Group (eds) Diagnosis and treatment of depression. Quo Vadis?. Montpelier, France; Sanofi Group 1987: 91-175
-
7
Colonna L, Petit M, Lepine J P.
Bromocriptine in affective disorders.
J Affect Disord.
1979;
1
173-177
-
8
Ferszt R, Kühl K-P, Bode L, Severus E W, Winzer B, Berghofer A, Beelilitz G, Brodhun B, Müler-Oerlinghausen B, Ludwig H.
Amantadine revisited: an open trial of amantadine sulfate treatment on chronically depressed patients with Borna disease virus infection.
Pharmacopsychiat.
1999;
32
142-147
-
9
Ferszt R, Severus E, Bode L, Brehm M, Kühl K-P, Berzewski H, Ludwig H.
Activated Borna disease virus in affective disorders.
Pharmacopsychiat.
1999;
32
93-98
-
10
Goldberg J F, Frye M A, Dunn R T.
Pramipexole in refractory bipolar depression.
Am J Psychiatry (Letter).
1999;
156
798
-
11 Goodman W K, Corrigan M, Evans D. Pramipexole in the treatment of major depression. Abstract presented at the congress of “European federation of Neurological Societies”. Siviglia, Spain; September 1998
-
12 Guy W. Adult Demogrpahic and Personal Inventory. In: Guy W (ed) ECDEU Assessment Manual for Psychopharmacology. Washington, DC; U.S. Government Printing Office 1976
-
13
Huber T J, Dietrich D, Emrich H M.
Possible use of amantadine in depression.
Pharmacopsychiat.
1999;
32
47-55
-
14
Kapur S, Mann J J.
Role of the dopaminergic system in depression.
Biol Psychiatry.
1992;
32
1-17
-
15
Kasper S, Barnas C, Heiden A, Volz H P, Laakmann G, Zeit H, Pfolz H.
Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy.
Eur Neuropsychopharmacol.
1997;
7
65-70
-
16
Little K Y.
Amphetamine, but not methylphenidate, predicts antidepressant response.
J Clin Psychopharmacol.
1988;
8
177-183
-
17
Nordin C, Siwers B, Bertilsson L.
Bromocriptine in depressive disorder: clinical and biochemical effects.
Acta Psychiatr Scand.
1981;
64
25-33
-
18
Nurnberger J J, Simmons-Ailing S, Kessler L.
Separate mechanisms for behavioral cardiovascular and hormonal responses to dextroamphetamine in man.
Psychopharmacol.
1984;
84
200-204
-
19
Parkes J D, Calver D M, Zilkha K J, Knill-Jones R P.
Conrolled trial of amantadine hydrochloride in Parkinson's Disease.
Lancet.
1970;
1
259-262
-
20
Parkinson Study Group .
Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study.
J Am Med Ass.
1997;
278
125-130
-
21
Perugi G, Akiskal H S, Micheli C, Musetti L, Paiano A, Quilici C, Rossi L, Cassano G B.
Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases.
J Affective Dis.
1997;
43
169-180
-
22
Perugi G, Akiskal H S, Lattanzi L, Cecconi D, Mastrocinque C, Patronelli A, Vignoli S, Bemi E.
The high prevalence of “soft” bipolar (II) features in atypical depression.
Comprehen Psychiatry.
1998;
39
(2)
63-71
-
23
Perugi G, Musetti L, Simonini E, Piagentini F, Cassano G B, Akiskal H S.
Gender-mediated clinical features of depressive illness. The importance of temperamental differences.
Br J Psychiatry.
1990;
157
835-841
-
24
Post R M, Gerner R H, Carman J S.
Effects of a dopamine agonist piribedil in depressed patients.
Arch Gen Psychiatry.
1978;
35
609-615
-
25
Rizzo M, Bioandrate P, Tognoni G, Morselli P L.
Amantadine in depression: relationship between behavioral effects and plasma levels.
Eur J Clin Pharmacol.
1973;
5
226-228
-
26 Rosenbaum J F, Fava M, Nierenberg A A, Sachs G S. Treatment-Resistant Mood Disorders. In: Gabbard GO (ed) Treatment of Psychiatric Disorders II (II ed). Vol. 46. Washington, DC; American Psychiatric Press 1995: 1275-1328
-
27
Rott R, Herzog S, Fleischer B, Winokur H, Amsterdam J, Dyson W, Koprowski H.
Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders.
Science.
1985;
228
755-756
-
28 Schatzberg A F, Cole J O, DeBattista C. Manual of Clinical Psychopharmacology, 3rd Edition. Washington, DC; American Psychiatric Press 1997
-
29
Schwab R S, England A C, Poskanzer D C, Young R R.
Amantadine in the treatment of Parkinson's disease.
J Am Med Association.
1969;
208
1168-1170
-
30
Silverstone T.
Response to bromocriptine distinguishes bipolar from unipolar depressions.
Lancet.
1984;
1
903-904
-
31
Szegedi A, Hillert A, Wetzel H, Klieser E, Gaebel W, Benkert O.
Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses.
Clin Neuropharmacol.
1997;
20
(1)
S36-S45
-
32
Theohar C, Fischer-Cornelssen K, Brosch H, Fischer E K, Petrovic D.
A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression.
Arzneimittelforschung.
1982;
32
(7)
783-787
-
33
Vale S, Espejel M A, Dominguez J C.
Amantadine in depression.
Lancet.
1971;
21-437
-
34
Waehrens J, Gerlach J.
Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in outpatients.
J Affect Disord.
1981;
3
193-202
-
35
Willner P.
Dopamine and depression: a review of recent evidence. I. Empirical studies.
Brain Res.
1983;
287
211-224
Giulio Perugi,MD
Institute of Psychiatry
University of Pisa
Via Roma 67
56100 Pisa
Italy
Telefon: + 50-992647
Fax: + 50-21581
eMail: gperugi@psico.med.unipi.it
